Evidence map›Paper›PMID 42291417›Full record

ArticlePeerJ2026

Nicotinamide metabolism-related signature and lncRNA regulatory network in kidney renal clear cell carcinoma.

Pei Dong, Lincong Zhao, Peiyao Shi, Ming Ma, Beixuan Huang, Zhenda Wang, Shaowei Zhang, Huan Liu

Abstract read
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pei Dong *The Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Lincong Zhao *The Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Peiyao ShiThe Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Ming MaThe Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Beixuan HuangThe Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Zhenda WangThe Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Shaowei ZhangThe Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.
Huan LiuThe Fourth Hospital of Hebei Medical University, State Grid Hebei Information & Telecommunication Company, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal carcinoma ranks among the most lethal cancers, primarily attributed to its atypical symptoms and high metastatic potential. The metabolism of nicotinamide (NAM) plays a significant role in the progression of various tumors. However, investigations into the impact of the NAM metabolism-related signature (NMRS) in kidney renal clear cell carcinoma (KIRC) remain insufficient. Clinical and RNA sequencing data (RNA-seq) from 541 KIRC tissues and 72 adjacent normal tissues were extracted from TCGA. NAM metabolism-related genes (NMRGs) were identified through the Molecular Signatures Database. Cox regression analyses (univariate/multivariate) were conducted to develop NMRS. Time-dependent ROC curve analysis showed that this method had good accuracy in predicting 1-year (AUC = 0.691), 3-year (AUC = 0.749), and 5-year (AUC = 0.764) survival. The Receiver Operating Characteristic (ROC) curve from the external RECA-EU dataset (AUC = 0.682) highlights the accurate prognostic assessment of the NMRS. Overall survival (OS) rates across distinct risk groups were compared using KM analysis. The Cox proportional hazards model assessed the influence of clinicopathological factors and risk scores on survival outcomes (HR = 1.437, 95% CI [1.232-1.676];

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNiacinamideRNA, Long NoncodingFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMalePrognosisROC CurveNiacinamideRNA, Long NoncodingCoxKIRClncRNAmiRNANMRGs

Identifiers

PMID42291417
PMCPMC13262547

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.